BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q2 EPS by 6c; Guides FY11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $57.54 -1.66%
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q2 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $110.63 million versus the consensus estimate of $105.9 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loews Corp. (L) Reports Q3 EPS of $1.50
- AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
- Entergy (ETR) Tops Q3 EPS by 31c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
